Abstract
Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field. COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).
Highlights
Cardiovascular diseases (CVD) remain the main cause of death worldwide despite technological and medical advances and is responsible for debilitating a significant number of patients annually
The immediate benefits of this Action will be the advancement of scientific collaboration across Europe and the unification of transcriptomics research in CVD through the network, involving clinical, academic, and industrial partners
A broader coordinated structure can significantly enhance existing collaborations between groups. This Cooperation in Science and Technology (COST) Action is well-suited for strengthening ongoing collaborations and establishing new ones by the creation of a large, interdisciplinary, and international network to jointly orchestrate and strategically plan integrated activities that will result in meaningful advancements in the field and, eventually, in healthcare
Summary
Cardiovascular diseases (CVD) remain the main cause of death worldwide despite technological and medical advances and is responsible for debilitating a significant number of patients annually. There are relatively isolated research groups working on the same subject and sometimes using different standards to generate data, making it harder to compare and reproduce results This is true when aiming to develop products for personalized medicine because they must deliver accurate information and high reproducibility. CardioRNA members aim to refine and implement guidelines for transcriptomic studies in CVD, tackling the whole investigation pipeline to improve comparison between studies from different laboratories and reproducibility of results, allowing faster development of new RNA-based tools for personalized medicine. This Action aims to enable enhancement and continuity of the network efforts in improving the understanding of the transcriptome in the cardiovascular context and advancement of personalized medicine. It has the goal to provide a platform to train the generation of researchers and students in the field
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
